Clinical trials: Allogeneic Stem Cell Transplantation
Acute Leukemia, Myeloid Leukemia
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
This is a multicenter, open-label study in people aged 18 and older with relapsed or refractory acute myeloid leukemia. It has two parts.
- Conditions
- Acute Leukemia, Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07157514
- Testing
- 131I-apamistamab, Fludarabine, Cyclophosphamide
- Volunteers
- 306 people
- Sponsor
- Actinium Pharmaceuticals
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
The purpose of this study is to evaluate the multi-lineage hematopoietic chimerism for unrelated umbilical cord blood (UCB) grafts pooled from two to three cord blood units.
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT01500161
- Testing
- Busulfan, Clofarabine, Fludarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Texas Oncology Cancer Center
Rhinovirus, Upper Respiratory Tract Infection
A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection
This is a randomized, double-blind, placebo-controlled study of vapendavir treatment of laboratory-confirmed and symptomatic HRV infection of the upper respiratory tract in allogeneic and autologous stem cell transplant subjects.
- Trial name
- NCT03024177
- Testing
- Vapendavir
- Sponsor
- Vaxart
Tibial Fracture
Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture
Although the majority of tibial fractures heal normally, some fractures may not heal within the usual time frame and is known as delayed bone healing within 4 to 6 months and absence of bone healing within 9 to 12 months in the…
- Trial name
- ALLOB-TF2 (NCT04432389)
- Testing
- ALLOB
- Where
- 39 sites in Belgium, Czechia and 5 more
- Volunteers
- 178 people
- Sponsor
- Bone Therapeutics S.A
Hematopoietic Stem Cells
Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation
The purpose of this study is to evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in…
- Trial name
- NCT03657160
- Testing
- Vedolizumab
- Where
- 139 sites in United States, Argentina and 25 more
- Volunteers
- 343 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
CB-012 is an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets C-type lectin-like molecule-1 (CLL-1). This is a Phase 1 study to evaluate the safety, preliminary efficacy, and pharmacokinetics, of CB-012 (the…
- Trial name
- AMpLify (NCT06128044)
- Testing
- CB-012
- Where
- 10 sites in United States
- Volunteers
- 12 people
- Sponsor
- Caribou Biosciences, Inc.
Acute Myocardial Infarction
Stem Cell in Acute Myocardial Infarction
The study will perform UC-MSCs transplantation in 2 groups and 1 control group with standard treatment. Each group consists of 5 subjects.
- Trial name
- AMI (NCT04340609)
- Testing
- Mesenchymal Stem Cells
- Where
- Indonesia
- Volunteers
- 4 people
- Sponsor
- PT. Prodia Stem Cell Indonesia
Patients Transplanted With NiCord/CordIn (Omidubicel)
Long Term Follow Up Protocol for NiCord®/CordIn™ (Omidubicel) Patients
This is an observational study that will monitor clinical outcomes of patients who have received a NiCord®/CordIn™ (omidubicel) transplant as part of a GC clinical interventional study and meet the eligibility criteria for this…
- Trial name
- NCT02039557
- Testing
- NiCord®/CordIn™ (omidubicel)
- Where
- 10 sites in United States, Netherlands and 2 more
- Volunteers
- 33 people
- Sponsor
- Gamida Cell ltd
Hematologic Malignancy, Acute Leukemia
Study to Characterize Mismatched to Fully HLA-Matched Ossium HPC, Marrow and Living Donor Transplantation in Patients With Hematologic Malignancies
Prospective, multi-center open label study of HLA-partially to fully matched allogeneic cryopreserved deceased donor bone marrow transplantation and living donor transplantation for patients with hematologic malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT07710781
- Testing
- Ossium HPC, Marrow, Standard of care living donor - Haplo Related, Standard of care living donor - Mismatched Unrelated
- Volunteers
- 300 people
- Sponsor
- Ossium Health, Inc.
B Cell Malignancy
Safety and Efficacy of ThisCART22 in Patients With Refractory or Relapsed B Cell Malignancies
This is a single-center, nonrandomized, open-label, study to evaluate the safety and clinical activity of allogeneic CAR-T targeting CD22 in patients with refractory or relapsed CD22-positive B cell malignancies
- Trial name
- NCT04601181
- Testing
- ThisCART22 cells injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Fundamenta Therapeutics, Ltd.
Acute Myeloid Leukemia, AML, Adult
FT538 in Subjects With Advanced Hematologic Malignancies
This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM).
- Conditions
- Acute Myeloid Leukemia, AML, Adult, Multiple Myeloma, Myeloma
- Trial name
- NCT04614636
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- Fate Therapeutics
Adenovirus
The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation
This study was designed to assess the safety, overall tolerability, and antiviral activity of "short course" brincidofovir (BCV) therapy, as compared with current standard of care (SoC), for the treatment of adenovirus (AdV)…
- Trial name
- AdAPT (NCT03339401)
- Testing
- Standard of Care, Brincidofovir
- Where
- 36 sites in United States, France and 7 more
- Volunteers
- 29 people
- Sponsor
- Jazz Pharmaceuticals
Lymphoma
Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
An observational database analysis, using existing data of patients diagnosed with Classical Hodgkin Lymphoma.
- Trial name
- NCT03200977
- Testing
- Non-Interventional
- Where
- 2 sites in United States
- Volunteers
- 95 people
- Sponsor
- Bristol-Myers Squibb
Degenerative Disc Disease
Trinity Evolution in Posterior or Transforaminal Lumbar Interbody Fusion (PLIF/TLIF)
The purpose of this study is to utilize Trinity Evolution in conjunction with an interbody spacer and supplemental posterior fixation of the surgeon's choice and to follow the patients to measure the clinical outcomes and rate of…
- Trial name
- TLF (NCT00965380)
- Where
- 15 sites in United States
- Volunteers
- 207 people
- Sponsor
- Orthofix Inc.
HCC - Hepatocellular Carcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer
This is an investigator initiated trial to assess the efficacy and safety of a GPC3-targeting CAR-T therapy (REVO-UWD-03) in the HCC and Lung Cancer.
- Trial name
- Wondercel-UWD3 (NCT06653023)
- Testing
- Universal CAR-T cells injection for treating HCC and NSCLC, MMF Immunosuppression
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Wondercel Biotech (ShenZhen)
Prostate Cancer
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
The primary objective of this study is to compare the duration of survival between patients receiving docetaxel in combination with the GVAX® vaccine for prostate cancer versus patients receiving docetaxel and prednisone…
- Trial name
- NCT00133224
- Testing
- Immunotherapy allogeneic GM-CSF secreting cellular vaccine, Chemotherapy (docetaxel and prednisone)
- Where
- 115 sites in United States, Belgium and 8 more
- Volunteers
- 408 people
- Sponsor
- Cell Genesys
Myocardial Fibrosis
A Trial of Cardiac Injections of iMP Cells During CABG Surgery
Injury to the heart, which may occur following a heart attack or owing to the mechanical effect of high blood pressure, leads to scarring (fibrosis) of the heart muscle.
- Trial name
- NCT03515291
- Testing
- iMP cells, Control injection
- Volunteers
- 50 people
- Sponsor
- Cell Therapy Ltd.
Acute Ischemic Stroke
Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Acute Ischemic Stroke
This is a multicenter, randomized, double-blind, placebo-controlled, dose-Escalation clinical study to investigate the safety and efficacy of EPCs transplantation in Acute ischemic stroke.
- Trial name
- NCT05993884
- Testing
- iEPCs
- Where
- 2 sites in China
- Volunteers
- 27 people
- Sponsor
- Allife Medical Science and Technology Co., Ltd.
Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation
A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant
The purpose of this study was to confirm a safe dose and schedule as well as the preliminary efficacy of siremadlin alone, and in combination with donor lymphocyte infusion (DLI), in adult participants with Acute Myeloid Leukemia…
- Trial name
- NCT05447663
- Testing
- Siremadlin
- Where
- 6 sites in Germany, Italy and 1 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Acute Myeloid Leukemia (AML), Cancer
A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute Myeloid Leukemia (AML) participants compared to Best Supportive Care (BSC) when…
- Trial name
- VIALE-T (NCT04161885)
- Testing
- Venetoclax, Azacitidine, Best Supportive Care (BSC)
- Where
- 165 sites in United States, Australia and 16 more
- Volunteers
- 465 people
- Sponsor
- AbbVie